Drug facts

Semaglutide sold as a research peptide

By David Chen·Editor·Reviewed September 2026

What is being sold²

The product is a vial sold from a website, usually alongside vials of other peptides, with a milligram figure on it and wording somewhere on the page saying it is for laboratory research. FDA reviewed one such site in July 2026 and wrote to its operators. Its letter lists the products by the names the site used — “Tirzepatide,” “Semaglutide,” “Retatrutide” and four others — and concludes that they are “unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act.”

The research wording did not change that conclusion. FDA’s footnote reads: “Despite statements on your product labeling marketing your products ‘for research use only’ and ‘not for human or animal consumption,’ evidence obtained from your website establishes that your products are intended to be drugs for human use.” An earlier letter, to a seller whose site offered “Semaglutide” (or “Sema”) among others, says the same of labeling that read “RESEARCH USE ONLY” and “INTENDED AS A RESEARCH CHEMICAL ONLY.” FDA posted four such letters on one day in December 2024, for “introducing unapproved GLP-1s, including semaglutide, tirzepatide and/or retatrutide products into interstate commerce.”³

So the label on the vial is a disclaimer about the seller’s intent, not a description of what the buyer is expected to do with it. FDA read the websites and decided what the products were for.

What FDA has said¹

FDA keeps a standing page on unapproved GLP-1 drugs used for weight loss, and one of its sections is about this exact category. In full:

FDA has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled “for research purposes” or “not for human consumption.” These products have been sold directly to consumers for human use with dosing instructions. The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health.

Two words in that passage are doing the work. Falsely labeled: FDA treats the research wording as a fiction it has already seen through. Unknown quality: nobody has checked the contents, the sterility or the strength, and there is no mechanism by which anybody would. The same page says compounded drugs are not FDA approved and that the agency “does not review compounded drugs for safety, effectiveness or quality before they are marketed”⁵ — and a research vial is a step further out than that, because no pharmacy, prescriber or state board is in the transaction at all.

FDA also acts at the border. It has established an import alert (66-80) “to help stop GLP-1 active pharmaceutical ingredients (APIs) that have potential quality concerns from entering the U.S. supply chain,” which is the ingredient these vials are filled from.

Why there are no mixing instructions here²

Readers arrive at pages like this one wanting a number: how much bacteriostatic water, how many units, how to work out a dose from a milligram figure. This page has none of that, and FDA’s own reasoning is why. The footnote quoted above continues:

In addition to the cited drug claims, you market bacteriostatic water alongside a “peptide guide” and “peptide calculator,” resources that collectively provide the means to prepare an injectable drug for human administration.

The mixing arithmetic is not neutral information sitting beside the sale. FDA counted it as part of the evidence that the products were intended as drugs for people. A site that publishes the calculator is supplying the missing half of an unapproved injection, and this one will not.

There is a second reason, and it is in the adverse-event reports below: the arithmetic is where people get hurt.

Which semaglutide is in the powder¹

“Semaglutide” on a website is not a specification. FDA says of compounded supply that some products “may be the salt forms”:

These salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients than are used in the approved drugs. The agency does not have information on whether these salts have the same chemical and pharmacologic properties as the active ingredient in the approved drug, and we are not aware of any lawful basis for their use in compounding.

That is written about pharmacies, which are licensed and inspected. A research-peptide seller is under no obligation to tell a buyer which form is in the vial, and FDA’s summary of these sellers is that the products are of unknown quality. The published evidence on this site — every trial figure on side effects, long-term safety and whether it works — was measured on the base form of semaglutide in an approved product. None of it transfers to an unidentified powder.

FDA has also described labels that are simply false: it is “aware of fraudulent compounded semaglutide and tirzepatide marketed in the U.S. that contain false information on the product label,” including cases where “the compounding pharmacies identified on the labels of the products do not exist,” and others naming a real pharmacy that did not make the product.

What went wrong with doses⁴

FDA published a separate alert about dosing errors with compounded injectable semaglutide in multiple-dose vials — the same physical situation a research vial creates, a person drawing a small volume out of a vial with a syringe. It reports adverse events “some requiring hospitalization,” and it is specific about the size of the errors:

• Five to twenty times the intended dose. In the majority of reports, patients drew up more than the prescribed amount, and “administered five to 20 times more than the intended dose of semaglutide.”
• Units mistaken for units. In several reports people were told to draw a 5-unit dose on a 1 mL insulin syringe and “mistakenly administered 50 units instead.”
• Prescribers miscalculating too. One provider “intended to dose 0.25 milligrams (5 units), but prescribed 25 units instead”; another prescribed 20 units instead of 2, affecting three patients.
• Why. FDA writes that many of these patients “lacked experience with self-injections,” and that unfamiliarity with drawing from a vial, “coupled with confusion between different units of measurement (e.g., milliliters, milligrams and ‘units’) may have contributed to dosing errors.”
• Concentrations vary. “Product concentrations also may vary depending on the compounder, and a single compounder may offer multiple concentrations,” so a number that was right for the last vial can be wrong for this one.

The reported consequences, in FDA’s words: gastrointestinal effects such as nausea, vomiting and abdominal pain, fainting, headache, migraine, dehydration, acute pancreatitis and gallstones, with some patients seeking medical attention or admitted to hospital. FDA adds that the approved label’s overdose information describes severe nausea, severe vomiting and severe low blood sugar, and that “a prolonged period of observation and treatment for overdose symptoms may be necessary due to the long half-life of semaglutide of about one week.”

A week is the part worth sitting with. An overdose of this drug cannot be waited out in an afternoon. Acute pancreatitis is on that list, and it is also a warning in the approved label.

The label on the vial¹

Two of FDA’s handling points apply to any vial, however it was obtained: it recommends discarding a multiple-dose vial of a sterile medication within 28 days of first use — “even if medication remains in the vial” and even if the supplier says longer — and a new sterile needle and syringe for every dose, because reuse “can result in contamination of the medication.” It also says not to use an injectable GLP-1 that “arrives warm or with insufficient refrigeration.” More on storage and shelf life.

What a legal route looks like

FDA’s recommendation for anyone considering a non-approved version is two sentences long: compounded drugs “should only be used in patients whose medical needs cannot be met by an FDA-approved drug,” and patients “should obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy.”¹ A research-peptide website is neither of those things.

• What a compounded preparation is, who may legally make one, and what that does and does not guarantee: what compounded semaglutide is.
• The risks FDA has named for compounded semaglutide, and its report count: is compounded semaglutide safe?
• Checking a seller before paying: four checks, ten minutes.
• What the licensed telehealth route actually costs, seller by seller: the price index.

This page reports FDA’s statements and its letters, quoted and attributed, and adds no instructions of its own. It is not medical advice, and it deliberately contains no reconstitution volumes, bacteriostatic-water amounts or dose arithmetic — what to inject, and from what, is a prescriber’s decision with a product that has a label. See the medical disclaimer.